Peptides Being Studied in Stroke Recovery Research
What Scientists Are Exploring
Important: Anyone recovering from a stroke should consult a neurologist, physician, rehabilitation specialist, or qualified functional medicine practitioner before considering any emerging therapies. This article is for educational purposes only and does not constitute medical advice.
Research Availability Assessment
Before writing a single word of analysis, this section documents what evidence actually exists for each peptide discussed. Transparency about evidence quality is fundamental to responsible scientific communication. The table below summarizes the current state of the literature for each compound.
| Peptide | Human Studies? | Animal Studies? | Evidence Level | Key Gaps |
|---|---|---|---|---|
| Cerebrolysin | Yes — multiple RCTs, meta-analyses, Cochrane reviews; 14 RCTs pooled (N=2,884) | Yes — extensive | ● Moderate–Strong | Inconsistent results across trials; methodological heterogeneity; most trials small |
| SEMAX | Yes — limited; primarily Russian clinical studies; one notable 110-patient trial (2018) | Yes — extensive preclinical rat models | ● Moderate (preclinical), Limited (human) | Western independent replication lacking; small human sample sizes; no large RCTs |
| BPC-157 | No — no published human stroke trials. Small human trials exist for GI conditions only | Yes — rat hippocampal ischemia/reperfusion models (Vukojić et al., 2020) | ● Limited (animal only for stroke) | No human stroke data. All stroke findings preclinical only. Cannot draw human conclusions |
| TB-500 (Thymosin β4) | No — no published human stroke trials. Cardiac human studies exist | Yes — rat stroke/TBI models (Morris, Chopp et al.; Wayne State University) | ● Limited (animal only for stroke) | No human stroke data. Promising preclinical findings have not yet progressed to clinical trials |
| GHK-Cu | No — no published human stroke or neuroprotection trials. Skin/wound human trials only | Yes — rodent models for cognition, brain injury, and intracerebral hemorrhage | ● Limited (animal only for neuro) | No human neurological data. Neuroprotection findings entirely preclinical |
Three of the five peptides discussed in this article — BPC-157, TB-500, and GHK-Cu — have no published human clinical trials in stroke recovery. All stroke-related findings for these compounds come from animal models. This distinction is maintained clearly throughout the article. Cerebrolysin has the strongest human evidence base; SEMAX has limited human data primarily from Eastern European research settings. The article discusses all five compounds but clearly delineates what level of evidence supports each claim.
Introduction
Every 40 seconds, someone in the United States has a stroke. Every 3 minutes and 31 seconds, someone dies from one. For the millions who survive, the road that follows — relearning to walk, to speak, to remember — is often longer and harder than the event itself. And for many stroke survivors and their families, the pace of conventional rehabilitation can feel frustratingly slow against the urgency of everything that has been lost.
It is in this context — the urgent need for better recovery tools — that a growing body of researchers has turned their attention to a class of molecules called peptides. These are short chains of amino acids, the same building blocks that make up proteins, and they interact with biological systems in remarkably specific ways. Some peptides occur naturally in the body. Others are synthesized in laboratories. And a handful are now being studied in the context of brain injury, stroke recovery, and neurological repair.
This article examines five peptides that have appeared in the stroke and neuroprotection research literature: Cerebrolysin, SEMAX, BPC-157, Thymosin Beta-4 (TB-500), and GHK-Cu. It explains what each one is, what the published science actually shows, and — critically — where the evidence is strong, where it is limited, and where it does not yet exist at all for human beings.
The goal is not to promote any compound or suggest any course of action. The goal is to give curious, intelligent readers an honest, plain-English look at an active area of scientific investigation — so that if you or someone you love is navigating stroke recovery, you can ask better questions of the specialists who are best placed to answer them.
Anyone recovering from a stroke should consult a neurologist, physician, rehabilitation specialist, or qualified functional medicine practitioner before considering any emerging therapies. Nothing in this article constitutes medical advice or a treatment recommendation.
Understanding Stroke
Before we can talk about what researchers are studying, it helps to understand what a stroke actually does to the brain — because that context is what makes the science meaningful.
Think of your brain as a city powered by an intricate network of blood vessels. Every neighborhood in that city — the parts responsible for movement, speech, memory, vision — depends on a constant supply of blood carrying oxygen and glucose. A stroke happens when that supply is suddenly cut off to one area. It is like a power blackout in part of the city. Without power, the cells in that area begin to die rapidly. In the most common type of stroke — an ischemic stroke, which accounts for about 87% of all strokes — a blood clot blocks an artery. In a hemorrhagic stroke, a blood vessel ruptures and bleeds into the brain.
What makes stroke so devastating is its speed. Brain cells are extraordinarily sensitive to oxygen deprivation. Within minutes of a blocked artery, neurons — the brain’s information-carrying cells — begin dying at an estimated rate of 1.9 million per minute. The standard medical phrase is blunt: “time is brain.”
ischemic (blood clot)
per minute during stroke
treatment (tPA)
Even after the initial damage, a second wave of harm unfolds over the following hours and days. Inflammation — the brain’s emergency response — rushes to the affected area. Like a fire crew that accidentally damages the buildings around a fire, this inflammation can injure brain tissue that survived the initial event. Additionally, the absence of blood flow creates what researchers call an “ischemic penumbra” — a ring of tissue around the dead zone that is injured but potentially saveable, if the right conditions are created quickly enough.
Recovery after stroke depends on the brain’s remarkable ability to adapt — a property scientists call neuroplasticity. Neuroplasticity is the brain’s ability to reorganize itself, forming new connections and rewiring pathways around damaged areas. Think of it like a city rebuilding after a disaster: new roads are built, old detours become permanent routes, and neighbors help carry functions that a single district can no longer manage alone. This is why rehabilitation matters enormously — and why researchers are interested in compounds that might support or accelerate this process.
A stroke cuts off blood to part of the brain, killing cells rapidly. Recovery depends on the brain’s ability to rebuild and rewire — a process called neuroplasticity. Researchers are studying whether certain compounds can support this rebuilding process, reduce the damage from post-stroke inflammation, and help the brain heal more effectively.
Why Researchers Study Peptides for Stroke
If you’ve ever wondered why peptides specifically have attracted scientific attention in neurological research, the answer comes down to a few key properties that make them particularly interesting tools for studying the brain.
The brain is protected by something called the blood-brain barrier — think of it as a very selective bouncer at the most exclusive club in your body. This barrier prevents most substances in the bloodstream from entering the brain. It is a critical protection mechanism, but it also makes it extremely difficult to get therapeutic molecules into the brain when it needs help. Many pharmaceutical drugs fail in neurological contexts not because they lack biological activity, but because they cannot cross this barrier in meaningful concentrations.
Some peptides — particularly small ones — can cross the blood-brain barrier more readily than larger molecules. This property makes them potentially valuable as tools for studying how to influence brain function and support recovery processes. Additionally, peptides interact with specific biological targets. Where a broad pharmaceutical might affect dozens of systems simultaneously, a peptide can be designed or selected to interact with one particular pathway — making it easier for researchers to study specific mechanisms.
In the context of stroke specifically, researchers are interested in compounds that may do several things: reduce the inflammatory damage that follows a stroke, support the survival of neurons that are injured but not yet dead, stimulate the production of neurotrophic factors (growth proteins that help neurons survive and form new connections), and promote the growth of new blood vessels in damaged areas — a process called angiogenesis.
“The brain after a stroke is not simply dead tissue surrounded by healthy tissue. It is a dynamic environment where injury, inflammation, and attempted repair are all happening simultaneously — and researchers are looking for ways to tip that balance toward recovery.”
It is important to say clearly that despite decades of research and hundreds of clinical trials, no compound — peptide or otherwise — has been proven to reliably accelerate stroke recovery beyond the established standards of care: rapid treatment of the acute event, followed by early, intensive physical and speech rehabilitation. The field remains active precisely because the need is so great and the solutions remain incomplete.
Peptides interest neurological researchers because some can reach the brain more easily than larger drugs, and because they can be designed to interact with specific repair processes. Scientists are looking for compounds that reduce post-stroke inflammation, protect surviving neurons, and support the brain’s natural healing mechanisms. The search is ongoing — no peptide has been proven to replace standard stroke treatment and rehabilitation.
The Five Peptides Researchers Are Studying
Here is a plain-English introduction to each of the five compounds appearing in the stroke recovery research literature. Each entry includes what the compound is, where it comes from, and why researchers have taken an interest in it — followed by the evidence assessment established in the opening section of this article.
1. Cerebrolysin
Moderate–Strong Human EvidenceCerebrolysin is not a single peptide but a mixture of small neuropeptides and amino acids derived from purified pig brain protein. It has been used in clinical medicine in parts of Europe and Asia for several decades, and it has the largest body of human clinical trial evidence of any compound discussed in this article.
The compound is thought to work by mimicking the effects of naturally occurring neurotrophic factors — proteins that support the survival, growth, and maintenance of neurons. Think of neurotrophic factors as fertilizer for brain cells. After a stroke, the brain produces some of these proteins naturally as part of its repair response, but researchers have explored whether supplying additional neurotrophic activity through Cerebrolysin might enhance recovery.
2. SEMAX
Moderate Preclinical / Limited HumanSEMAX is a seven-amino-acid synthetic peptide developed by Russian scientists in the 1980s and 1990s as a modified fragment of a naturally occurring hormone called ACTH. Researchers became interested in SEMAX because of its interactions with BDNF (Brain-Derived Neurotrophic Factor) — one of the most important proteins for neuron survival and the formation of new neural connections.
BDNF is like a growth signal specifically for brain cells. After a stroke, BDNF levels in the damaged area drop significantly. Research has explored whether SEMAX can support BDNF levels during recovery, and whether this influence on brain chemistry translates into measurable improvements in neurological function.
3. BPC-157
Limited — Animal Models Only for StrokeBPC-157 is a 15-amino-acid synthetic peptide derived from a protein found in human gastric juice. Its name — Body Protection Compound — reflects its original identification as a naturally occurring protective substance in the stomach lining. It has been studied extensively in animal models for its effects on tissue repair, wound healing, and more recently, neurological injury.
It is important to state clearly: BPC-157 has no published human clinical trials for stroke recovery. All neurological findings come from rodent studies. This does not make the research uninteresting — animal models are an essential part of how science builds understanding — but it means any discussion of BPC-157 and stroke must be understood as early-stage preclinical investigation, not established therapy.
4. TB-500 (Thymosin Beta-4)
Limited — Animal Models Only for StrokeThymosin Beta-4 (TB-4, or TB-500 as it is commonly known in research contexts) is a naturally occurring peptide found in virtually every cell of the body. It plays an important role in regulating actin — a protein that forms part of the structural skeleton of cells and is involved in cellular movement and repair. TB-500 has been studied by researchers at Wayne State University and elsewhere for its potential in both cardiac and neurological injury contexts.
Like BPC-157, TB-500 has no published human clinical trials specifically in stroke recovery. The neurological research comes from rat models. However, the mechanism of research is distinct and scientifically interesting: TB-500 appears to promote the migration of neural stem cells, support the growth of new blood vessels in damaged brain tissue, and stimulate the production of support cells called oligodendrocytes that protect and maintain neurons.
5. GHK-Cu (Copper Peptide)
Limited — Animal Models Only for NeuroGHK-Cu is a tripeptide — a chain of just three amino acids (glycine, histidine, and lysine) that forms a complex with copper. It occurs naturally in human plasma, and its levels decline with age. It has been studied since the 1970s primarily in the context of wound healing and skin biology, where its ability to stimulate collagen synthesis and reduce inflammation is well documented in the research literature.
More recently, researchers have explored GHK-Cu’s potential relevance to neurological contexts. Studies in aging rodent models and brain injury models have examined whether GHK-Cu influences BDNF and NGF (Nerve Growth Factor) — two proteins critical for neuron health — and whether it reduces neuroinflammation. No human neurological clinical trials exist for GHK-Cu. All neuroprotection research is preclinical.
What Human Research Shows
This section covers only findings from studies conducted in human beings. We separate these clearly from animal findings because the distinction is fundamental to scientific literacy.
Cerebrolysin — The Strongest Human Evidence
Cerebrolysin has been the subject of more human clinical research in stroke than any other peptide discussed here. A 2025 systematic review and meta-analysis published in the journal Cureus (Patel et al.) pooled data from 14 randomized controlled trials involving 2,884 patients and found that Cerebrolysin significantly improved neurological recovery scores (measured on the standard NIH Stroke Scale) compared to placebo, with a mean difference of +1.39 points.
A 2024 systematic review published in Cureus (Hassan et al.) covering PubMed, Medline, Embase, and the Cochrane Library through September 2024 found that Cerebrolysin “demonstrated consistent improvement in early neurological function and motor recovery” with a number-needed-to-treat of 7.1 for early neurological score improvements — meaning that for approximately every 7 patients treated, one additional patient showed meaningful early improvement compared to placebo.
A 2022 randomized pilot study published in the journal Stroke (American Heart Association) examined Cerebrolysin combined with speech therapy in patients with aphasia (difficulty speaking) after acute ischemic stroke, enrolling 132 patients between 2020 and 2022. The study explored whether the combination produced better language recovery outcomes than speech therapy alone.
The picture is not entirely consistent. A 2023 Cochrane review (Ziganshina et al., referenced in the Patel meta-analysis) assessed the existing trials and noted methodological concerns — many studies are small, funding relationships vary, and the quality of evidence across trials is heterogeneous. The evidence is meaningful but not definitive, and Cerebrolysin is not currently standard of care in the United States or most Western countries.
Cerebrolysin has been tested in real human stroke patients in multiple studies. The data suggests it may help with early neurological recovery, but results are mixed across different studies and it is not a standard treatment. Think of it as a compound with promising but still-debated human evidence.
SEMAX — Limited but Existing Human Data
SEMAX has been the subject of limited human research, primarily conducted in Russia. A 2018 study published in the Journal of Neurology and Psychiatry (Gusev et al.) examined 110 patients after ischemic stroke, dividing them into early and late rehabilitation groups each subdivided into SEMAX-treated and untreated subgroups. The study found that SEMAX administration was associated with increased plasma BDNF levels, which correlated positively with improvements in functional scores (measured on the Barthel Index — a standard scale for activities of daily living) and motor performance.
The limitation of this research is significant: it represents a relatively small number of patients, it comes primarily from a single research tradition, and it has not been independently replicated in large-scale randomized controlled trials by Western research institutions. The findings are interesting and support further investigation, but they do not constitute the level of evidence required to establish SEMAX as a proven therapy.
SEMAX has been used under medical supervision in Russia for neurological conditions, but this clinical use in one regulatory context does not constitute the rigorous, replicated clinical evidence that would support broader therapeutic claims.
BPC-157, TB-500 (Thymosin Beta-4), and GHK-Cu have no published human clinical trials in stroke recovery. Any discussion of their potential relevance to stroke is based entirely on animal model research. This is an important distinction that any responsible source should make clearly.
What Animal Research Shows
Animal research — primarily studies conducted in rats and mice — is the foundation on which most early neurological research is built. It is how scientists develop hypotheses, identify promising mechanisms, and decide whether a compound is worth the enormous investment required to test in humans. It does not tell us what will happen in people, but it provides essential biological clues.
BPC-157 in Stroke and Brain Injury Models
A 2020 study published in the journal Brain and Behavior (Vukojić et al.; PMID 32558293) tested BPC-157 in rats subjected to bilateral clamping of the carotid arteries — a standard laboratory model of hippocampal ischemia, which mimics the brain oxygen deprivation of a stroke. The study found that BPC-157 treatment counteracted both early and delayed neural damage, with treated rats achieving full functional recovery on memory, locomotion, and coordination tests at 24 and 72 hours after the injury.
The researchers also examined gene expression in the hippocampal tissue and found significant changes in genes related to cell survival, nitric oxide signaling, and vascular growth — suggesting a plausible molecular mechanism for the observed effects. The study’s authors described the findings as suggesting that “these beneficial BPC-157 effects may provide a novel therapeutic solution for stroke.”
A 2021 review of BPC-157 and the central nervous system (published in a neurological sciences journal) summarized the compound’s preclinical CNS findings across stroke, spinal cord injury, and dopaminergic system models, describing it as having “pleiotropic beneficial effects” that may be particularly relevant to the gut-brain axis.
Thymosin Beta-4 (TB-500) in Stroke Models
Some of the most substantive TB-500 neurological research has been conducted by a team at Wayne State University, led by researchers Michael Chopp and Zheng Gang Zhang. A 2014 study published in the Journal of Neurological Sciences (Morris, Chopp et al.) conducted a dose-response analysis of Thymosin Beta-4 treatment in acute stroke rat models, examining how different doses influenced neurological recovery outcomes.
The Wayne State research group found that TB-500 treatment in rat stroke models was associated with increased neural stem cell migration from the brain’s neurogenic zones toward areas of ischemic injury — essentially, the brain trying to repair itself by sending new cell candidates to the damaged area, with TB-500 appearing to support and amplify this process. They also observed increased angiogenesis (new blood vessel formation) and oligodendrogenesis (formation of the support cells that maintain neurons) in treated animals.
A 2012 study by the same group, published in the Annals of the New York Academy of Sciences, explored TB-500 in traumatic brain injury models and found both neuroprotective effects (reduced initial damage) and neurorestorative effects (improved functional recovery during the rehabilitation period) when treatment was initiated 6 hours after injury.
GHK-Cu in Brain Injury and Aging Models
GHK-Cu’s neurological research base is more diffuse than the other compounds — it spans aging cognition models, spinal cord injury studies, and intracerebral hemorrhage models rather than focusing specifically on ischemic stroke. Research reviewed in the University of Washington’s ResearchWorks archive found that a short-term course of GHK-Cu in middle-aged mice (20–22 months old) improved spatial learning and memory performance, with associated reductions in hippocampal inflammation markers and improvements in neuronal architecture.
Studies in intracerebral hemorrhage models found that GHK-Cu treatment improved neurological functional recovery, reduced brain edema (swelling), and increased neuronal survival — findings linked to changes in gene regulation including microRNA-146a-3p expression and reduced levels of AQP4, a protein associated with brain swelling.
GHK-Cu has also been shown in multiple cell culture and animal studies to stimulate the production of BDNF and NGF — the same neurotrophic factors that researchers associate with SEMAX and Cerebrolysin’s proposed mechanisms. Whether this translates to meaningful neurological outcomes in humans remains an open question.
In laboratory animals, BPC-157, TB-500, and GHK-Cu have all shown interesting results in brain injury and stroke models — reduced damage, improved recovery, and support for the brain’s own repair processes. This is scientifically meaningful preliminary evidence. But laboratory animals are not people, and these findings must be tested in human trials before any conclusions about people can be drawn.
Limitations and Criticisms
An honest assessment of this research field requires a clear-eyed look at its limitations. These are not reasons to dismiss the science — they are reasons to hold it carefully, interpret it accurately, and understand exactly what it does and does not tell us.
The translation problem. The history of stroke research is full of compounds that showed spectacular results in animal models and then failed to replicate in human clinical trials. This is not a peptide-specific problem — it is a fundamental challenge in neurological drug development. The complexity of human stroke — different locations, different sizes, different patient ages and comorbidities — creates a heterogeneity that rodent models cannot fully capture. A rat stroke is controlled and reproducible. A human stroke is not.
Small sample sizes. Even the human studies that exist for Cerebrolysin and SEMAX are relatively small by the standards of modern evidence-based medicine. While the Cerebrolysin meta-analysis pooled 2,884 patients across 14 trials, many individual trials included only 60–100 patients. For comparison, major Phase III pharmaceutical trials often involve tens of thousands of participants. Small trials are more susceptible to statistical noise, chance findings, and publication bias.
Geographic concentration of research. Much of the SEMAX and some of the Cerebrolysin research originates from Russian and Eastern European research institutions. Independent replication in Western research settings — with different patient populations, different methodological standards, and different conflicts of interest — is limited. Independent replication is a cornerstone of scientific credibility.
Funding and conflicts of interest. Cerebrolysin is manufactured by a pharmaceutical company (EVER Neuro Pharma), and some of the clinical trials have been conducted with industry involvement. This does not automatically invalidate the findings, but it is a factor that the scientific community considers when evaluating the evidence base. Independent, publicly funded trials are generally considered more credible.
No established dosing, timing, or delivery protocols. For compounds like BPC-157 and TB-500 where no human stroke trials exist, there are no established protocols for what dose, what timing, what delivery method, or what patient population might be relevant — because that research has not been done. Discussing these compounds in a stroke recovery context is discussing scientific hypotheses, not established approaches.
Anyone recovering from a stroke should consult a neurologist, physician, rehabilitation specialist, or qualified functional medicine practitioner before considering any emerging therapies. The limitations described above are real and significant. Standard rehabilitation remains the only evidence-based approach to stroke recovery with broad clinical consensus behind it.
Questions Patients Should Ask Healthcare Providers
If you or a loved one is navigating stroke recovery and you have read about these compounds, the most valuable thing this article can do is help you ask better questions of the medical professionals who are best positioned to answer them. Here are questions worth bringing to a neurologist, rehabilitation physician, or functional medicine practitioner.
What We Still Don’t Know
Good science is as honest about its uncertainties as it is about its findings. Here is what the research has not yet established — and what would need to happen for the field to advance.
For Cerebrolysin: Whether the neurological score improvements seen in trials translate into meaningful functional independence in daily life over the long term. Whether the compound works differently in different stroke subtypes, sizes, or locations. The optimal dosing window, duration, and patient selection criteria. Why results have been inconsistent across different trial settings.
For SEMAX: Whether the BDNF elevation observed in the Russian human study translates to meaningfully better functional outcomes in larger, independently conducted trials. How SEMAX compares head-to-head with other neuroprotective strategies. Whether the findings from Eastern European populations generalize to other demographics.
For BPC-157: Whether any of the preclinical findings replicate in human stroke patients at all. What dose, timing, and delivery route would even be relevant for human neurological application. Whether the compound can cross the blood-brain barrier in humans in therapeutically relevant concentrations.
For TB-500 (Thymosin Beta-4): Whether the neural stem cell migration and angiogenesis findings observed in rat models occur in the same way in the much more complex human brain. Whether there is a viable human clinical trial pathway for this compound in stroke. The dose-response relationship in humans for any neurological indication.
For GHK-Cu: Whether the neuroprotective gene expression changes observed in rodent models translate to meaningful brain protection in humans. Whether the compound’s well-documented wound healing properties extend to neurological repair in human clinical contexts. There is an almost complete absence of human neurological data.
The honest answer to “what do we still not know?” about most of these compounds in the stroke context is: quite a lot. That is not a failure of the science — it is the normal state of a young and active research field. But it is important context for anyone trying to evaluate what the existing findings actually mean.
Conclusion
Stroke is one of the most urgent unmet needs in medicine. Despite decades of research, rehabilitation remains the cornerstone of recovery, and the search for pharmacological interventions that meaningfully accelerate healing continues. In this context, the peptides discussed here represent an active and scientifically legitimate area of investigation — with honest acknowledgment that the evidence base varies enormously across compounds.
Cerebrolysin has the most developed human clinical evidence base, with multiple randomized controlled trials and meta-analyses showing modest but consistent improvements in early neurological recovery. The evidence is real but not definitive, and the compound is not a standard of care in Western medicine. SEMAX has interesting human data from a limited number of studies, primarily from Russia, that warrants further independent investigation but cannot yet support broad clinical conclusions.
BPC-157, TB-500, and GHK-Cu present fascinating preclinical findings in animal models of brain injury and stroke. The mechanisms being explored — neurotrophic factor support, neural stem cell migration, angiogenesis, neuroprotection from oxidative stress — are scientifically meaningful and biologically plausible. But none of these compounds have been tested in human stroke patients. They are, at this stage, promising hypotheses awaiting the clinical validation that would allow any meaningful conclusions about people.
For anyone navigating stroke recovery — as a patient, a caregiver, or a concerned family member — the most important guidance this article can offer is this: the published science is worth understanding, and it is worth discussing with specialists who can contextualize it within your specific situation. Intensive, early rehabilitation remains the most evidence-backed intervention available. Emerging compounds may one day complement that picture. The research is ongoing, and the science deserves to be followed honestly.
Anyone recovering from a stroke should consult a neurologist, physician, rehabilitation specialist, or qualified functional medicine practitioner before considering any emerging therapies. No compound discussed in this article is approved by the FDA for stroke recovery. All products referenced are research compounds for laboratory use only. This article does not constitute medical advice.
All products offered by Bio Grade Peptide are intended strictly for laboratory research and scientific investigation purposes only. These products are not intended for human or animal consumption. They are not approved by the FDA or any regulatory authority for diagnostic or therapeutic use and are not intended to diagnose, treat, cure, or prevent any disease or medical condition. This article is intended solely for educational and informational purposes and should not be interpreted as medical advice. Research on the compounds discussed is ongoing and many findings are preliminary or limited to animal models. Consult a licensed medical professional for any health-related questions.
References and Further Reading
Every major claim in this article is sourced. The following references are provided for readers who wish to review primary literature directly. Links are to PubMed, PMC, or published journal pages where available.
- 1. Patel PN, Mangal D, Patel K. (2025). Safety and Efficacy of Cerebrolysin for Neurorecovery After Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of 14 Randomized Controlled Trials. Cureus. DOI: 10.7759/cureus.91054. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12465088/
- 2. Hassan BD, Dabas MM, Kanemitsu K, et al. (2024). Evaluating the Effectiveness of Neuroprotective Strategies in Enhancing Post-stroke Recovery: A Systematic Review of Meta-Analyses and Clinical Trials. Cureus. DOI: 10.7759/cureus.71343. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555301/
- 3. Gharagozli K, Harandi AA, Houshmand S, et al. (2017). Efficacy and safety of Cerebrolysin treatment in early recovery after acute ischemic stroke: a randomized, placebo-controlled, double-blinded, multicenter clinical trial. PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652261/
- 4. Mures̔anu DF et al. (2024). Speech Therapy Combined With Cerebrolysin in Enhancing Nonfluent Aphasia Recovery After Acute Ischemic Stroke: ESCAS Randomized Pilot Study. Stroke (American Heart Association). https://www.ahajournals.org/doi/10.1161/STROKEAHA.124.049834
- 5. Gusev EI et al. (2018). The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Journal of Neurology and Psychiatry, Vol. 3. https://www.researchgate.net/publication/325375504
- 6. Ivanova SA et al. (2021). Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4–7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusion. PMC/NCBI. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226508/
- 7. Vukojić J et al. (2020). The effect of pentadecapeptide BPC 157 on hippocampal ischemia/reperfusion injuries in rats. Brain and Behavior. PMID: 32558293. https://pubmed.ncbi.nlm.nih.gov/32558293/ | Full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428500/
- 8. Sikirić P et al. (2021). Pentadecapeptide BPC 157 and the central nervous system. PubMed. PMID: 34380875. https://pubmed.ncbi.nlm.nih.gov/34380875/
- 9. Morris DC, Chopp M, Zhang L, Zhang ZG. (2010). Thymosin beta4: a candidate for treatment of stroke? Annals of the New York Academy of Sciences, 1194:112–7. PMID: 20536457. https://pubmed.ncbi.nlm.nih.gov/20536457/
- 10. Morris DC, Cui Y, Cheung WL, et al. (2014). A dose-response study of thymosin β4 for the treatment of acute stroke. Journal of Neurological Sciences, 345(1–2):61–67. https://doi.org/10.1016/j.jns.2014.07.006
- 11. Xiong Y, Mahmood A, Meng Y, et al. (2012). Neuroprotective and neurorestorative effects of thymosin β4 treatment following experimental traumatic brain injury. Annals of the New York Academy of Sciences, 1270:51–58. PMID: 23050817. https://pubmed.ncbi.nlm.nih.gov/23050817/
- 12. Pickart L, Margolina A. (2018). Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
- 13. University of Washington ResearchWorks. Short-term treatment of mice with GHK peptide enhances resilience to age-related cognitive decline. https://digital.lib.washington.edu/researchworks/items/61b49b6c
- 14. American Stroke Association. Stroke Statistics. https://www.stroke.org/en/about-stroke/stroke-risk-factors/stroke-statistics
- 15. National Institute of Neurological Disorders and Stroke (NINDS). Stroke: Hope Through Research. https://www.ninds.nih.gov/health-information/disorders/stroke
